Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Chimerix, Inc. (CMRX)

2.24   0.02 (0.9%) 12-06 09:53
Open: 2.22 Pre. Close: 2.22
High: 2.26 Low: 2.21
Volume: 43,275 Market Cap: 197(M)

Technical analysis

as of: 2022-12-06 9:17:39 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.79     One year: 3.26
Support: Support1: 1.99    Support2: 1.74
Resistance: Resistance1: 2.39    Resistance2: 2.79
Pivot: 2.2
Moving Average: MA(5): 2.23     MA(20): 2.14
MA(100): 2.11     MA(250): 3.48
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 68.1     %D(3): 74.7
RSI: RSI(14): 57.4
52-week: High: 7.42  Low: 1.26
Average Vol(K): 3-Month: 1,121 (K)  10-Days: 1,067 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CMRX ] has closed below upper band by 44.0%. Bollinger Bands are 53.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 2.32 - 2.34 2.34 - 2.35
Low: 2.15 - 2.17 2.17 - 2.18
Close: 2.2 - 2.22 2.22 - 2.24

Company Description

Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.

Headline News

Sun, 04 Dec 2022
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update - MarketBeat

Mon, 21 Nov 2022
Chimerix Earnings Perspective: Return On Invested Capital - Chimerix (NASDAQ:CMRX) - Benzinga

Mon, 14 Nov 2022
Chimerix: Big Doings At A Small Biotech (NASDAQ:CMRX) - Seeking Alpha

Fri, 11 Nov 2022
Should You Hold Chimerix Inc (CMRX) Stock Friday Morning? - InvestorsObserver

Thu, 10 Nov 2022
Chimerix rejects calls for liquidation from Rubric Capital Management (NASDAQ:CMRX) - Seeking Alpha

Thu, 10 Nov 2022
Rubric Capital Makes Huge Add to Chimerix (CMRX) Position - Nasdaq

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Outperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 88 (M)
% Held by Insiders 7.144e+007 (%)
% Held by Institutions 9.9 (%)
Shares Short 3,420 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -7.601e+007
EPS Est Next Qtl -0.48
EPS Est This Year -1.63
EPS Est Next Year -1.86
Book Value (p.s.) 0
Profit Margin (%) 464.7
Operating Margin (%) -230.3
Return on Assets (ttm) -22.3
Return on Equity (ttm) 81.1
Qtrly Rev. Growth 30
Gross Profit (p.s.) 301.11
Sales Per Share 3.06111e+007
EBITDA (p.s.) -6.65185e+007
Qtrly Earnings Growth 1.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -61 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0.77

Stock Dividends

Dividend 0
Forward Dividend 3.48e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.